Evidence map›Paper›PMID 36136141›Full record

SynthesisEuropean journal of clinical pharmacology2022

Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis.

Xiaomei Wang, Demei Zhang, Yanxia Ren, Jingjing Han, Guangling Li, Xueya Guo

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in European journal of clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiaomei WangDepartment of Cardiology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Demei ZhangDepartment of Cardiology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Yanxia RenDepartment of Cardiology, First Hospital of Lanzhou University, Lanzhou University, Lanzhou, China.
Jingjing HanDepartment of Cardiology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Guangling LiDepartment of Cardiology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.
Xueya GuoDepartment of Cardiology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China. guoxueya2006@126.com.
Lanzhou University · CNLanzhou University Second Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPostoperative atrial fibrillation/flutter (POAF) is one of the most common cardiac complications after lung surgery. We aimed to assess the safety and efficacy of pharmacological interventions for new-onset POAF prophylaxis in patients with lung cancer after lung surgery.

methodsPubMed, Embase, Web of Science, Scopus, and the Cochrane Library were searched to identify randomized controlled trials comparing the effects of pharmacological interventions to prevent POAF following lung surgery.

resultsA total number of 19 studies with 2,922 participants were included. Pharmacological interventions significantly reduced the incidence of POAF (odds ratio [OR] 0.36, 95% confidence interval [95% CI] 0.26-0.52) while did not increase the incidence of severe pulmonary complications (OR 1.17, 95% CI 0.57-2.41) after lung surgery compared with placebo/usual care. Among different trials, beta-blockers appeared to be the most effective with an OR of 0.13 (95% CI, 0.07-0.27) and a number needed-to-treat (NNT) of 3.63 and was considered safe with no serious adverse events recorded. The risk of POAF decreased from 25.6 to 11.4% (P < 0.001) overall and from 34.2 to 6.7% (P < 0.001) with beta-blockers as monotherapy. Pharmacological interventions did not reduce the 30-day mortality (OR 0.89, 95% CI 0.43-1.84, I

conclusionCurrent clinical evidence supports the effectiveness of pharmacological intervention with beta-blockers, amiodarone, magnesium sulfate, or calcium-channel blockers to reduce the incidence of POAF after lung surgery in patients with lung cancer. In the absence of contraindications, prophylaxis with beta-blockers seems to be the most effective of the treatments studied.

Indexed as

AmiodaroneAtrial FibrillationCardiac Surgical ProceduresLung NeoplasmsMyocardial InfarctionAdrenergic beta-AntagonistsCalciumHumansLungMagnesium SulfatePostoperative ComplicationsAdrenergic beta-AntagonistsAmiodaroneCalciumMagnesium SulfateLung surgeryMeta-analysisPharmacological interventionsPostoperative atrial fibrillationProphylaxis

Identifiers

PMID36136141
OpenAlexW4296899808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.